Coronavirus (COVID-19) Collection
Parallel detection of SARS-CoV-2 RNA and nucleocapsid antigen in nasopharyngeal specimens from a COVID-19 patient screening cohort
The ongoing pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) poses serious challenges for healthcare. Unprecedented demands on molecular testing have revealed a number of practical limitations of the PCR-based COVID-19 diagnostics. In this situation, additional and less demanding laboratory tools for SARS-CoV-2 detection, such as testing for viral antigens, merit consideration. A series of studies have reported the performance of numerous qualitative immunochromatographic rapid diagnostic tests (Young et al., 2020; Chaimayo et al., 2020; Lanser et al., 2020), as well as several variants of automated quantitative assays (Hirotsu et al., 2021; Pollock et al., 2021).Comparison of Roche and Lumipulse quantitative SARS-CoV-2 antigen test performance using automated systems for the diagnosis of COVID-19
Quantitative reverse transcription PCR (RT-qPCR) is a highly sensitive and specific assay and is considered the gold standard test for detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In addition, RT-qPCR can detect viral RNA at a very low copy number by amplification over 40 cycles. Therefore, RT-qPCR is a powerful tool for the diagnosis of SARS-CoV-2 infection.Analytical performances of the point-of-care SIENNA™ COVID-19 Antigen Rapid Test for the detection of SARS-CoV-2 nucleocapsid protein in nasopharyngeal swabs: A prospective evaluation during the COVID-19 second wave in France
The coronavirus disease 2019 (COVID-19) pandemic continues to spread across the world. Hence, there is an urgent need for rapid, simple, and accurate tests to diagnose severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. While currently recommended nucleic acid amplification tests (NAAT), such as real-time reverse transcription polymerase chain reaction (rtRT-PCR) assays, remain the gold standard cornerstone for the diagnosis of SARS-CoV-2 infection (Smithgall et al., 2020; Rai et al., 2021), immunological methods can also be used to detect viral antigens (Dinnes et al., 2020; Li and Li, 2020; Rai et al., 2021).Prospective study of 1308 nasopharyngeal swabs from 1033 patients using the LUMIPULSE SARS-CoV-2 antigen test: Comparison with RT-qPCR
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has spread rapidly around the world. Approximately 80% of infected patients with coronavirus disease 2019 (COVID-19) develop mild symptoms and recover without specific treatment (Matheson and Lehner, 2020). However, 20% of patients deteriorate rapidly within 7–10 days of symptom onset, and 25% of these patients will face mechanical ventilation and high mortality rates (Matheson and Lehner, 2020).
